(EMAILWIRE.COM, August 01, 2018 ) The global 3D cell culture market is projected to reach USD 1,720.3 Million by 2022 from USD 682.8 Million in 2017, at a CAGR of 20.3%. Factors such as rising focus on developing alternative methods for animal testing, funding initiatives from government and private investors, technological advancements and product launches, and growing awareness are driving the growth of the market.

The report segments the global market into by type of product, application, end user, and region.

Based on product, the market is segmented into scaffold-based 3D cell culture, scaffold-free 3D cell culture, microfluidics-based 3D cell culture, and magnetic levitation and 3D bioprinting. The scaffold-based 3D cell culture products segment is expected to account for the largest market share in 2017, and is projected to register the highest CAGR during the forecast period. The high growth in this segment is attributed to the ability of scaffold-based products to mimic in vivo conditions, thus driving their adoption among end users.

Download PDF brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=191072847

By type, the scaffold-based 3D cell culture market is segmented into hydrogels/ECM analogs, solid scaffolds, and micropatterned surfaces. The hydrogels/ECM segment analogs are expected to account for the largest share of the scaffold-based market owing to their wide acceptance among researchers.

The global market, by applications, is segmented into cancer and stem cell research, drug discovery and toxicology testing, and tissue engineering & regenerative medicine. The cancer and stem cell research segment is estimated to account for the largest market share in 2017. Growth of this application segment is attributed to increasing incidence of cancer and significant funding initiatives for cancer research from government as well as private organizations.

Based on end users, the 3D cell culture market is segmented into pharmaceutical & biotechnology companies and research institutes. In 2017, pharmaceutical and biotechnology companies are expected to form the largest end-user segment. The presence of a large number of pharmaceutical and biotechnology companies, increasing R&D spending in these companies, and growing focus on alternative testing models instead of animal techniques are the key drivers for this end-user segment.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.